Jasbir Seehra

CEO

Board Member

Chairman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

KROS

Current role

CEO, Board Member, Chairman

2024-07-01–present

ELOX

Board Member

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Keros Therapeutics, Inc. (KROS)	President and Chief Executive Officer	$700,000	—	$1,426,280	—	$398,125	$15,799	$2,540,204
2024	Keros Therapeutics, Inc. (KROS)	Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer	$699,039	—	—	$5,104,488	$455,000	$14,666	$6,273,192
2023	Keros Therapeutics, Inc. (KROS)	Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer	$649,135	$107,250	—	$7,806,530	$357,500	$11,661	$8,932,076
2022	Keros Therapeutics, Inc. (KROS)	Ph.D. Chief Executive Officer and Chair Keith Regnante Chief Financial Officer	$610,817	$60,500	—	$5,475,349	$302,500	$11,767	$6,460,934
2021	Keros Therapeutics, Inc. (KROS)	Chief Executive Officer and Director	$556,800	—	—	$6,325,872	$348,000	$3,287	$7,233,959
2020	Keros Therapeutics, Inc. (KROS)	Chief Executive Officer and Director	$521,014	—	—	$8,713,137	$262,650	$3,498	$9,500,299
2019	Keros Therapeutics, Inc. (KROS)	Chief Executive Officer and Director	$485,100	—	—	$15,379	$194,040	—	$694,519

No earnings-call appearances or filed executive changes recorded yet.